Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
96 hedge funds and large institutions have $37.8M invested in Endocyte, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 8 closing their positions.
263% more call options, than puts
Call options by funds: $167K | Put options by funds: $46K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
7% more funds holding
Funds holding: 90 → 96 (+6)
20% less capital invested
Capital invested by funds: $47.5M → $37.8M (-$9.68M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$407K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$365K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$311K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$267K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.69M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.2M |
| 3 |
Renaissance Technologies
New York
|
-$399K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$307K |
| 5 |
SIM
Spark Investment Management
New York
|
-$230K |
ECYT Hedge Fund Activity: Q4 2016 in Review
96 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2016, worth a combined $37.8M — down 20% from $47.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ECYT positions and 8 closed out — a net gain of 6 holders — while 30 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $407K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.69M sold.
- 96 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2016, up from 90 in Q3 2016.
- Funds reported $37.8M of Endocyte, Inc. Common Stock stock for Q4 2016, down 20% quarter-over-quarter.
- 14 funds opened new Endocyte, Inc. Common Stock positions in Q4 2016 and 8 closed out, a net change of +6 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q4 2016 was Morgan Stanley, an estimated $407K added.
- The largest Endocyte, Inc. Common Stock seller in Q4 2016 was Baker Bros. Advisors, an estimated $2.69M sold.
Based on aggregated 13F filings for Q4 2016.